New Self-Administered Inhaled Gene Therapy Linked to Mesothelioma Survival

A team of doctors in Japan have developed a new oral inhaled gene therapy for the treatment of mesothelioma. This is a new gene therapy that mesothelioma patients can self-administer, much like an asthma inhaler. There’s new evidence that therapies that prevent cancer cells from forming new blood vessels may offer a better way to approach malignant pleural mesothelioma. Gene therapy has attracted attention in recent years. A new study suggests that inhalable gene drugs are effective treatments for asbestos-induced malignant pleural mesothelioma. Gene Therapy Treatments Mesothelioma is the most deadly of several diseases caused by asbestos exposure, including lung cancer and asbestosis. Most people who develop mesothelioma live less than a year after diagnosis. It is most common in … Continue reading New Self-Administered Inhaled Gene Therapy Linked to Mesothelioma Survival »

Genomic Experts Report Most Complete Picture of Mesothelioma to Date

Genomic Experts Report Most Complete Picture of Mesothelioma to Date

Australian and American genomic experts have completed a key step in improving the treatment of pleural mesothelioma. A new study gives results from a large study of malignant pleural mesothelioma Pleural mesothelioma is a type of cancer that develops on the thin layer of tissue that covers the lungs and chest wall. Asbestos causes mesothelioma and other asbestos-related diseases. Asbestos was used in thousands of industrial, commercial, construction, automotive, and consumer products. Pleural mesothelioma occurs in about 2,000 people in the United States every year. Scientists at the National Centre for Asbestos-Related Disease have taken a dramatic leap forward in the understanding of pleural mesothelioma. DNA Genes Impact Personalized Treatment Plans Previous genomic studies of malignant pleural mesothelioma were limited. … Continue reading Genomic Experts Report Most Complete Picture of Mesothelioma to Date »

New Advancements in Personalized Medicine for Mesothelioma

New Advancements in Personalized Medicine for Mesothelioma

Genomics is a new branch of medicine that involves using a patient’s genetic information to create personalized treatment. New research has begun looking at genetic personalized medicine for mesothelioma. Students from the University of Montana are developing personalized medicine for mesothelioma. Personalized Medicine and Mesothelioma Treatment Mesothelioma is a rare rare and aggressive cancer often caused by asbestos exposure. Environmental exposure to asbestos often causes a higher incidence of malignant mesothelioma. There are approximately 2,000 cases of mesothelioma diagnosed in the U.S. every year. Current standard of care involves a multi-targeted drug combination of Pemetrexid and Cisplatin. This is the only FDA approved chemotherapy for mesothelioma. Chemotherapy is a group of toxic drugs that kill mesothelioma cells by damaging their … Continue reading New Advancements in Personalized Medicine for Mesothelioma »

Hope for Mesothelioma Patients with Genetic Predisposition (Germline PVs) for Cancer

Mesothelioma Patients with Genetic Predisposition for Cancer are Candidates for Personalized Medicine

Malignant pleural mesothelioma is a tumor caused by asbestos exposure. Recently, the United States Food and Drug Administration approved immunotherapy treatment for mesothelioma. But the efficacy of available treatments is still limited. Researchers are still evaluating these new therapeutic approaches. They are also working to identify subgroups of patients who could benefit from precision medicine. Precision medicine uses information about a person’s tumor to find out how well a treatment is working. One of these groups could be represented by patients with an inherited cancer syndrome. These are caused by germline pathogenic variants (PVs) in DNA repair genes. A germline pathogenic variant is a gene variant (or mutation) that is passed from parent to child. These germline PVs are hereditary. … Continue reading Hope for Mesothelioma Patients with Genetic Predisposition (Germline PVs) for Cancer »

New Enzyme Study Highlights a Potential New Mesothelioma Treatment

New Enzyme Study Highlights a Potential New Mesothelioma Treatment

Maryland researchers say an enzyme in mesothelioma tissues could be key to fighting this deadly cancer. Doctors at the University of Maryland say the enzyme, called Transglutaminase 2 (TG2), plays an important role in the inhibition of RNA synthesis which, in turn, can influence the development and spread of malignant mesothelioma. A New Target for Mesothelioma Therapy? Mesothelioma is a cancer of the lung linings that develops in response to asbestos exposure. Mesothelioma patients have a limited life expectancy. Chemotherapy with or without surgical resection is the standard of care. This poor clinical experience speaks to the need for new treatment strategies. Current mesothelioma treatments do not target cancer stem‐like (MCS) cells. MCS cells are a small part of aggressive … Continue reading New Enzyme Study Highlights a Potential New Mesothelioma Treatment »

MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine

MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine

A special issue was published in the Journal of Personalized Medicine. Dr. Alessandra Pulliero from the University of Genoa in Italy talks about microRNA. Specifically, the role of microRNA in cancer development and personalized medicine. A microRNA (miRNA) is a small part of an RNA molecule. MiRNAs play a key role in the regulation of gene expression in cells, including mesothelioma cells. Mesothelioma is a rare and aggressive cancer often caused by asbestos exposure. Asbestos also causes a progressive lung disease called asbestosis. Environmental exposure to asbestos often causes a higher incidence of malignant mesothelioma. Malignant mesothelioma is characterized by poor prognosis and short survival. Personalized Medicine and Mesothelioma Scientists now know that the role of miRNAs changes once they … Continue reading MicroRNAs in Cancer Development and Mesothelioma Personalized Medicine »

Precision Medicine Treatment: Gene-Targeting Mesothelioma

Precision Medicine Treatment: Gene-Targeting Mesothelioma

A new precision medicine treatment for mesothelioma comes from scientists in Italy. This form of mesothelioma occurs after asbestos exposure in people with a genetic mutation. The mutation is represented by patients with an inherited cancer syndrome. These patients typically have an even worse prognosis than other mesothelioma patients. But the Italian team came up with a way to target the mutated gene. This form of treatment is called precision medicine. Precision medicine treatment looks at the genetics of a patient to select a treatment that will work best for them. Discovery of a DNA Gene Mutation Malignant pleural mesothelioma is a rare and aggressive cancer caused by exposure to asbestos. Malignant mesothelioma is one of the most aggressive kinds … Continue reading Precision Medicine Treatment: Gene-Targeting Mesothelioma »

Genetic Mesothelioma Risk May Lead to Shorter Latency

genetic mesothelioma risk

A particular genetic risk for mesothelioma may be behind the few cases where cancer develops just a few years after asbestos exposure. That is the word from researchers at Australia’s Flinders University and the Asbestos Diseases Research Institute.  Latency is the time it takes after exposure to a cancer-causing agent for signs of cancer to show up. Malignant mesothelioma has one of the longest latency periods of any cancer. In most cases, it takes about 40 years for mesothelioma to develop. As a result, mesothelioma is rare in people under 65. But, in rare cases, mesothelioma develops earlier in life. These cases have sometimes been dismissed as being unrelated to asbestos. But in a new journal article, mesothelioma experts from … Continue reading Genetic Mesothelioma Risk May Lead to Shorter Latency »

New CAR-T Cell Therapy for Mesothelioma Circumvents Immune Suppression

CAR-T Cell Therapy

A new cancer treatment based on CAR-T cell therapy may have found a way to undermine a key protective mechanism in mesothelioma tumors. The treatment is called UCARTMESO. It is being developed by a French biopharmaceutical company called Cellectis. UCARTMESO targets cells that overexpress the protein mesothelin. It undermines some key genes in these cells preventing them from sending immune suppressive signals.  Immune suppressive elements in the area surrounding mesothelioma tumors have historically kept CAR-T cell therapy from working as well as it does for some other types of cancer.  But the developers of UCARTMESO say their approach may finally make CAR-T cell therapy a viable option for patients fighting asbestos cancer.  They presented their findings at the Society for … Continue reading New CAR-T Cell Therapy for Mesothelioma Circumvents Immune Suppression »

Immunotherapy Drug Durvalumab Shines in Most Recent Mesothelioma Trial

immunotherapy drug durvalumab

Another new study confirms what Johns Hopkins researchers have been banking on – that the immunotherapy drug durvalumab can make chemotherapy more effective for mesothelioma patients.  Durvalumab (IMFINZI) is an immune checkpoint inhibitor. It works by blocking the action of PD-1, a protein that mesothelioma cells use to protect themselves.  Researchers theorized that deactivating PD-1 with the immunotherapy drug durvalumab might make mesothelioma tumors more responsive to chemotherapy. The latest study results, published in Nature Medicine, suggest that they were right.  The findings could have implications for people around the world with inoperable malignant mesothelioma. How the Immunotherapy Drug Durvalumab Helps Fight Mesothelioma Durvalumab is one of several immune checkpoint inhibitors showing promise for mesothelioma in recent years. Keytruda (pembrolizumab) … Continue reading Immunotherapy Drug Durvalumab Shines in Most Recent Mesothelioma Trial »

Get your free copy of
“Surviving Mesothelioma” Today!